1
|
Yurayart C, Niae S, Limsivilai O, Thengchaisri N, Sattasathuchana P. Comparative analysis of the distribution and antifungal susceptibility of yeast species in cat facial hair and human nails. Sci Rep 2024; 14:14726. [PMID: 38926524 PMCID: PMC11208614 DOI: 10.1038/s41598-024-65730-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Accepted: 06/24/2024] [Indexed: 06/28/2024] Open
Abstract
Zoonotic yeast species have been implicated in disease development in both humans and cats. This study analyzed the yeast mycobiota present in feline facial hair and human nails and explored potential interspecies associations. A total of 118 biological specimens were examined, including 59 feline facial hair and 59 human nail samples. DNA extraction and DNA sequencing were performed to identify the specific yeast species. The most predominant yeast species in humans and cats were selected for antifungal susceptibility testing (itraconazole, ketoconazole, miconazole, and terbinafine). The findings unveiled diverse yeast species in cats and humans. Malassezia pachydermatis (45.8%) and Malassezia furfur (30.5%) were the most common yeast species in cats and humans, respectively. However, no significant correlation was detected between the yeast species identified in cats and their owners residing in the same household (p > 0.05). Miconazole exhibited the highest minimum inhibitory concentrations (MICs) against Malassezia pachydermatis and Malassezia furfur in both cat and human isolates, whereas terbinafine showed the lowest MICs against most Malassezia pachydermatis and Malassezia furfur in both cat and human isolates. Diverse yeast species in cat facial hair and human nails suggest possible cross-contamination among humans, pets, and environments.
Collapse
Affiliation(s)
- Chompoonek Yurayart
- Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand
| | - Sara Niae
- Faculty of Veterinary Science, Rajamangala University of Technology Srivijaya, Nakhon Si Thammarat, 80240, Thailand
| | - Orawan Limsivilai
- Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand
| | - Naris Thengchaisri
- Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd, Latyao, Jatujak, Bangkok, 10900, Thailand
| | - Panpicha Sattasathuchana
- Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd, Latyao, Jatujak, Bangkok, 10900, Thailand.
| |
Collapse
|
2
|
Díaz L, Castellá G, Bragulat MR, Cabañes FJ. ERG11 Gene Variability and Azole Susceptibility in Malassezia pachydermatis. Mycopathologia 2023; 188:21-34. [PMID: 36495417 PMCID: PMC10169892 DOI: 10.1007/s11046-022-00696-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 11/18/2022] [Indexed: 12/14/2022]
Abstract
Malassezia pachydermatis is part of the normal skin microbiota of various animal species but under certain circumstances becomes an opportunistic pathogen producing otitis and dermatitis. Commonly these Malassezia diseases are effectively treated using azoles. However, some cases of treatment failure have been reported. Alterations in the ERG11 gene have been associated with in vitro azole resistance in M. pachydermatis. In the present study, in vitro antifungal susceptibility of 89 different strains of M. pachydermatis isolated from different animal species and health status was studied. The susceptibility to fluconazole (FLZ), itraconazole (ITZ), ketoconazole and amphotericin B was tested by a disk diffusion method and 17 strains were also subjected to an ITZ E-test. Mueller-Hinton supplemented with 2% glucose and methylene blue was used as culture medium in both susceptibility assays. Multilocus sequence typing was performed in 30 selected strains using D1D2, ITS, CHS2 and β-tubulin genes. Also, ERG11 gene was sequenced. The four antifungals tested were highly effective against most of the strains. Only two strains showed no inhibition zone to antifungals and a strain showed an increased MIC to ITZ. The study of the ERG11 sequences revealed a high diversity of DNA sequences and a total of 23 amino acid substitutions, from which only two have been previously described. Also, three deleterious substitutions (A302T, G459D and G461D) previously associated with azole resistance in this yeast were recovered. A correlation between certain genotypes and ERG11 mutations was observed. Some of the ERG11 mutations recovered were correlated with a reduced susceptibility to azoles.
Collapse
Affiliation(s)
- Leyna Díaz
- Veterinary Mycology Group, Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain
| | - Gemma Castellá
- Veterinary Mycology Group, Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain.
- Grup de Micologia Veterinària, Departament de Sanitat i d'Anatomia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193, Bellaterra, Barcelona, Spain.
| | - M Rosa Bragulat
- Veterinary Mycology Group, Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain
| | - F Javier Cabañes
- Veterinary Mycology Group, Department of Animal Health and Anatomy, Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain
| |
Collapse
|
3
|
Tapes D, Skampardonis V, Chatzis MK, Apostolidis K, Athanasiou LV, Kasabalis D, Kokkinaki KCG, Katsogiannou EG, Petanides T, Leontides L, Saridomichelakis MN. Repeatability and reproducibility of microscopic examination of adhesive tape strip cytology slides for the quantification of
Malassezia
spp. in canine skin. Vet Dermatol 2022; 33:305-e71. [DOI: 10.1111/vde.13076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 01/27/2022] [Accepted: 02/07/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Dimitrios Tapes
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
- Veterinary Clinic, Army Veterinary Training and Health Center Stratigou N. Plastira Larisa Greece
| | - Vassilis Skampardonis
- Laboratory of Epidemiology and Animal Health Economics, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Manolis K. Chatzis
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Kosmas Apostolidis
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Labrini V. Athanasiou
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Dimitris Kasabalis
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | | | - Eleni G. Katsogiannou
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Theodoros Petanides
- Clinic of Medicine, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | - Leonidas Leontides
- Laboratory of Epidemiology and Animal Health Economics, Faculty of Veterinary Science University of Thessaly Karditsa Greece
| | | |
Collapse
|
4
|
Rhimi W, Theelen B, Boekhout T, Aneke CI, Otranto D, Cafarchia C. Conventional therapy and new antifungal drugs against Malassezia infections. Med Mycol 2021; 59:215-234. [PMID: 33099634 DOI: 10.1093/mmy/myaa087] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 09/14/2020] [Accepted: 09/29/2020] [Indexed: 12/18/2022] Open
Abstract
Malassezia yeasts are commensal microorganisms occurring on the skin of humans and animals causing dermatological disorders or systemic infections in severely immunocompromised hosts. Despite attempts to control such yeast infections with topical and systemic antifungals, recurrence of clinical signs of skin infections as well as treatment failure in preventing or treating Malassezia furfur fungemia have been reported most likely due to wrong management of these infections (e.g., due to early termination of treatment) or due to the occurrence of resistant phenomena. Standardized methods for in vitro antifungal susceptibility tests of these yeasts are still lacking, thus resulting in variable susceptibility profiles to azoles among Malassezia spp. and a lack of clinical breakpoints. The inherent limitations to the current pharmacological treatments for Malassezia infections both in humans and animals, stimulated the interest of the scientific community to discover new, effective antifungal drugs or substances to treat these infections. In this review, data about the in vivo and in vitro antifungal activity of the most commonly employed drugs (i.e., azoles, polyenes, allylamines, and echinocandins) against Malassezia yeasts, with a focus on human bloodstream infections, are summarized and their clinical implications are discussed. In addition, the usefulness of alternative compounds is discussed.
Collapse
Affiliation(s)
- Wafa Rhimi
- Dipartimento di Medicina Veterinaria, Università degli Studi "Aldo Moro", Bari, Italy
| | - Bart Theelen
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - Teun Boekhout
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute for Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, The Netherlands
| | - Chioma Inyang Aneke
- Dipartimento di Medicina Veterinaria, Università degli Studi "Aldo Moro", Bari, Italy.,Department of Veterinary Pathology and Microbiology, University of Nigeria, Nsukka, Nigeria
| | - Domenico Otranto
- Dipartimento di Medicina Veterinaria, Università degli Studi "Aldo Moro", Bari, Italy.,Faculty of Veterinary Sciences, Bu-Ali Sina University, Hamedan, Iran
| | - Claudia Cafarchia
- Dipartimento di Medicina Veterinaria, Università degli Studi "Aldo Moro", Bari, Italy
| |
Collapse
|
5
|
Sadeghi S, Kamrani A, Kuc U, Polissar N, Selukar S, Sadeghi S. Use of a modified Burow's solution to treat canine otitis externa: A randomised comparative clinical study. Vet Rec 2021; 190:e503. [PMID: 34091924 DOI: 10.1002/vetr.503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Given the increase in antimicrobial drug resistance of several pathogens that affect the ear, there is a need for alternative therapy for canine otitis externa (OE). We hypothesised that the efficacy of modified Burow's solution would be non-inferior to that of standard treatment with Surolan. METHODS The treatment success rate of a topical aluminum acetate 2% and betamethasone 0.1% (modified Burow's) otic solution was compared with that of a standard topical otic treatment of polymyxin B sulfate, prednisolone acetate and miconazole (Surolan) suspension in a prospective, open-label clinical trial. For 10 days, 142 dogs (232 ears) with OE were treated with modified Burow's solution or Surolan. The primary study endpoint was the cure rate at 10 days. Clinical efficacy was analysed as a secondary endpoint but without assessment for non-inferiority. RESULTS The 10-day OE cure rate was 65% and 59% in the Burow's and Surolan groups, respectively. The modified Burow's solution was non-inferior to Surolan at a non-inferiority margin of -11.5% and was more clinically effective than Surolan in dogs with OE caused by yeast or bacteria. CONCLUSION The results of this study demonstrate that modified Burow's solution is an effective treatment for OE in dogs.
Collapse
Affiliation(s)
- Sam Sadeghi
- Vellore Village Pet Hospital, Vaughan, Ontario, Canada
| | | | - Urszula Kuc
- Vellore Village Pet Hospital, Vaughan, Ontario, Canada
| | | | | | - Sina Sadeghi
- Vellore Village Pet Hospital, Vaughan, Ontario, Canada
| |
Collapse
|
6
|
Antifungal Resistance Regarding Malassezia pachydermatis: Where Are We Now? J Fungi (Basel) 2020; 6:jof6020093. [PMID: 32630397 PMCID: PMC7345795 DOI: 10.3390/jof6020093] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 06/19/2020] [Accepted: 06/22/2020] [Indexed: 12/29/2022] Open
Abstract
Malassezia pachydermatis is a yeast inhabiting the skin and ear canals in healthy dogs. In the presence of various predisposing conditions it can cause otitis and dermatitis, which are treated with multiple antifungal agents, mainly azole derivatives. This manuscript aims to review the available evidence regarding the occurrence of resistance phenomena in this organism. Various findings support the capacity of M. pachydermatis for developing resistance. These include some reports of treatment failure in dogs, the reduced antifungal activity found against yeast isolates sampled from dogs with exposure to antifungal drugs and strains exposed to antifungal agents in vitro, and the description of resistance mechanisms. At the same time, the data reviewed may suggest that the development of resistance is a rare eventuality in canine practice. For example, only three publications describe confirmed cases of treatment failure due to antifungal resistance, and most claims of resistance made by past studies are based on interpretive breakpoints that lack sound support from the clinical perspective. However, it is possible that resistant cases are underreported in literature, perhaps due to the difficulty of obtaining a laboratory confirmation given that a standard procedure for susceptibility testing of M. pachydermatis is still unavailable. These considerations highlight the need for maintaining surveillance for the possible emergence of clinically relevant resistance, hopefully through a shared strategy put in place by the scientific community.
Collapse
|
7
|
Guillot J, Bond R. Malassezia Yeasts in Veterinary Dermatology: An Updated Overview. Front Cell Infect Microbiol 2020; 10:79. [PMID: 32181160 PMCID: PMC7059102 DOI: 10.3389/fcimb.2020.00079] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Accepted: 02/17/2020] [Indexed: 12/23/2022] Open
Abstract
Lipophilic yeasts of the genus Malassezia are important skin commensals and opportunistic skin pathogens in a variety of animals. The species M. pachydermatis was first isolated from the skin of a captive Indian rhinoceros with an exfoliative dermatitis in 1925, recognized as an important otic pathogen of dogs in the 1950's, and finally accepted, after several years of controversy, as a common cause of canine dermatitis in the 1990's. Since then, there has been considerable research into the biology of Malassezia yeasts and their interaction with their animal hosts. In dogs and cats, M. pachydermatis is associated with ceruminous otitis externa and a "seborrhoeic" dermatitis, wherein pruritic, erythematous skin lesions, often with brown/black greasy, malodourous material matting hairs, preferentially develop in intertriginous areas. Skin disease is favored by folds, underlying hypersensitivity disorders, endocrinopathies, defects of cornification, and in cats, various visceral paraneoplastic syndromes. Diagnosis is based on detecting the yeast in compatible skin lesions, usually by cytology, and observing a clinical and mycological response to therapy. Treatment normally comprises topical or systemic azole therapy, often with miconazole-chlorhexidine shampoos or oral itraconazole or ketoconazole. Management of concurrent diseases is important to minimize relapses. Historically, wild-type Malassezia isolates from dogs and cats were typically susceptible to azoles, with the exception of fluconazole, but emerging azole resistance in field strains has recently been associated with either mutations or quadruplication of the ERG11 gene. These observations have prompted increased interest in alternative topical antifungal drugs, such as chlorhexidine, and various essential oils. Further clinical trials are awaited with interest.
Collapse
Affiliation(s)
- Jacques Guillot
- École Nationale Vétérinaire d'Alfort, BioPôle Alfort, EA Dynamyc, UPEC, EnvA, Maisons-Alfort, France
| | - Ross Bond
- Department of Clinical Sciences and Services, Royal Veterinary College, Hatfield, United Kingdom
| |
Collapse
|